To mitigate the risk of HF hospitalizations and mortality, guidelines advocate for the use of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor–neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists, beta-blockers, and sodium–glucose co-transporter 2 (SGLT-2) inhibitors. This evidence concerns the gene ACE and hydrops fetalis.